Catalog Products » CD200/OX-2, His, Cynomolgus
Manual
Manual
COAs

CD200/OX-2, His, Cynomolgus

CD200 and its receptors are highly expressed in the lung, on epithelial cells and leukocytes, and emerging evidence links dysregulation of the CD200 pathway with asthma. Moreover, pharmacological modulation of CD200 receptors was shown to improve clinical and inflammatory outcomes of preclinical asthma models.
$390.00
Z04109-100

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
CD200/OX-2 (Gln56-Gly257)
Accession # A0A2K5TQS2		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 23.66 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 45-55 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

CD200/OX-2, His, Cynomolgus

Immobilized CD200/OX-2, His, Cynomolgus, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Human CD200 R1, hFc Tag with the EC50 of 6.2ng/ml determined by ELISA. »

CD200/OX-2, His, Cynomolgus

The purity of CD200/OX-2, His, Cynomolgus is greater than 95% as determined by SEC-HPLC. »

CD200/OX-2, His, Cynomolgus

CD200/OX-2, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background CD200 and its receptors are highly expressed in the lung, on epithelial cells and leukocytes, and emerging evidence links dysregulation of the CD200 pathway with asthma. Moreover, pharmacological modulation of CD200 receptors was shown to improve clinical and inflammatory outcomes of preclinical asthma models.
Synonyms CD200; MOX1; MOX2; My033; MRC; OX-2; OX2
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.